Lilly rises after launch of weight-loss drug Mounjaro in India
Shares of drugmaker Eli Lilly LLY.N rise 1.77% to $852.32
Eli Lilly launches its blockbuster diabetes and weight-loss drug Mounjaro in India beating rival Novo Nordisk NOVOb.CO
The once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest dose
Novo's India team has been pushing the global leadership to launch its weight-loss drug, Wegovy, as early as 2025 in the country as opposed to the company's target of a 2026 launch
LLY stock up 10% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey







